FDAnews Device Daily Bulletin
June 17, 2008 | Vol. 5 No. 118
As part of a settlement in a lawsuit filed by Moms Against Mercury, the FDA has agreed to classify a controversial mercury-containing cavity filler by July 28, 2009.
Naviscan PET Systems reported clinical data using the positron emission mammography (PEM) Flex Solo II scanner in breast cancer management.
BioMedical Enterprises is launching its Barbed OSStaple (BOSS), a nitinol implant designed for internal fixation of bones.
Ernesto Bertarelli, the Swiss-Italian biotech billionaire, returned to the front line of business as his new $1.5 billion healthcare fund joined with Merrill Lynch to buy Euromedic, the Hungary-based medical diagnostics and dialysis group.
Obese children at risk of developing Type 2 diabetes may not be getting the news soon enough to take preventive action because the test used to gauge their condition is not sensitive enough, a new study suggests.
A high-technology company on Maui plans to double its work force as it manufactures and markets a new device for the pharmaceutical industry.
AVI BioPharma, Inc. announced that its partner in its cardiovascular program, Global Therapeutics, the cardiology unit of Cook Medical, has received CE Mark approval for a new cobalt chromium bare metal stent.
A new DNA microarray chip can predict severe disability and remission in patients with rheumatoid arthritis (RA), as presented at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.
InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange, announced the findings of new studies and analysis highlighting RESPeRATE — the only medical device cleared by the FDA and CE-approved for the treatment of hypertension.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.